報價延遲最少15分鐘:2025/08/01 16:55 EDT
盤後時段
|
||||
|
1.5 
|
|
|
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.53
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.59/-0.60
|
|
企業價值
176.32M
|
| 資產負債 |
|
每股賬面淨值
1.33
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
18.72M
|
|
每股收益
0.20
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
報價延遲最少15分鐘：2025/08/01 16:55 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib. |
